Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Single-Center Study of Exploring the β-hydroxybutyrate Supplementation and Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Locally Advanced Rectal Cancer

NCT07239466 is registered in ClinicalTrials.gov with Tao Zhang as lead sponsor.

NCT NCT07239466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07239466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Single-Center Study of Exploring the β-hydroxybutyrate Supplementation and Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Lead sponsor
Tao Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2026
Completion date
June 1, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, immunotherapy, radiotherapy, rectal cancer